Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Remimazolam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.42 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Remimazolam SCHEMBL23735014 | 1.00 | GABRA1 (0.42) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Remimazolam SCHEMBL29379415 | 1.00 | GABRA1 (0.42) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Remimazolam SCHEMBL29579211 | 1.00 | GABRA1 (0.42) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL21674324 | 0.95 | GABRA1 (0.41) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL22853791 | 0.94 | GABRA1 (0.40) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Remimazolam SCHEMBL20473322 | 0.94 | GABRA1 (0.39) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Remimazolam SCHEMBL20473302 | 0.94 | GABRA1 (0.39) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Remimazolam SCHEMBL1539505 | 0.93 | GABRA1 (0.38) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Remimazolam SCHEMBL825168 | 0.93 | GABRA1 (0.38) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Remimazolam SCHEMBL30788432 | 0.93 | GABRA1 (0.38) | GABRA1GABRA5GABRA3GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360144-A1 | DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM) | PAION UK LTD. (GB) | 2025-11-27 | — | — | US | claimed |
| EP-4556068-A2 | ORALLY INHALED AND NASAL BENZODIAZEPINES | Paion UK Limited (GB) | 2025-05-21 | — | — | EP | claimed |
| EP-3442539-B1 | ORALLY INHALED AND NASAL BENZODIAZEPINES | PAION UK LTD (GB) | 2025-04-09 | — | — | EP | claimed |
| US-20230346796-A1 | DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM) | PAION UK LTD. (GB) | 2023-11-02 | — | — | US | claimed |
| EP-2891494-B1 | METHOD FOR ADMINISTERING HYPNOTIC/SEDATIVE AGENT | PAION UK LTD (GB) | 2023-07-19 | — | — | EP | claimed |
| US-20220152045-A1 | DOSING REGIMEN OF SEDATIVE | PAION UK LIMITED (GB) | 2022-05-19 | — | — | US | claimed |
| US-11325911-B2 | Method for preparing 3-[(4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[ 1,2-a][1,4]benzodiazepin-4-yl]-propionic acid methyl ester, and compounds useful in said method | MOEHS IBERICA, S.L. | 2022-05-10 | — | — | US | claimed |
| US-11236064-B2 | Method for preparing 3-[(3S)-7-bromo-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-[1,4]-benzodiazepin-3-yl] propionic acid methyl ester, and compounds useful in that method | MOEHS IBERICA S.L. (ES) | 2022-02-01 | — | — | US | claimed |
| EP-3658545-B1 | METHOD FOR PREPARING 3-[(3S)-7-BROMO-2-OXO-5-(PYRIDIN-2-YL)-2,3-DIHYDRO-1H-[1,4]-BENZODIAZEPIN-3-YL]PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN THAT METHOD | MOEHS IBERICA SL (ES) | 2021-08-11 | — | — | EP | claimed |
| US-20210139452-A1 | METHOD FOR PREPARING 3-[(3S)-7-BROMO-2-OXO-5-(PYRIDIN-2-YL)-2,3-DIHYDRO-1H-[1,4]-BENZODIAZEPIN-3-YL] PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN THAT METHOD | MOEHS IBERICA S.L. (ES) | 2021-05-13 | — | — | US | claimed |
| US-20150224114-A1 | DOSING REGIMEN OF SEDATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | claimed |
| EP-2891494-A1 | METHOD FOR ADMINISTERING HYPNOTIC/SEDATIVE AGENT | ONO Pharmaceutical Co., Ltd. (JP) | 2015-07-08 | — | — | EP | claimed |
| US-20150148338-A1 | COMPOSITIONS COMPRISING SHORT-ACTING BENZODIAZEPINES | PAION UK LIMITED (GB) | 2015-05-28 | — | — | US | claimed |
| US-20120330007-A1 | PROCESS FOR PREPARING 3-[(4S)-8-BROMO-1-METHYL-6-(2-PYRIDINYL)-4H-IMIDAZO[1,2-A][1,4]BENZODIAZEPINE-4-YL]PROPIONIC ACID METHYL ESTER OR THE BENZENE SULFONATE SALT THEREOF, AND COMPOUNDS USEFUL IN THAT PROCESS | PAION UK LIMITED (GB) | 2012-12-27 | — | — | US | claimed |
| EP-2450039-A1 | Dosing regimen for sedation with CNS 7056 (Remimazolam) | PAION UK Ltd. (GB) | 2012-05-09 | — | — | EP | claimed |
| EP-2305647-A1 | Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process | PAION UK Limited (GB) | 2011-04-06 | — | — | EP | claimed |
| US-7485635-B2 | Short-acting benzodiazepines | CENES LIMITED (GB) | 2009-02-03 | — | — | US | claimed |
| EP-1183243-B1 | SHORT-ACTING BENZODIAZEPINES | CENES LTD (GB) | 2006-02-08 | — | — | EP | claimed |
| EP-1183243-A1 | SHORT-ACTING BENZODIAZEPINES | GLAXO GROUP LIMITED (GB) | 2002-03-06 | — | — | EP | claimed |
| WO-2000069836-A1 | SHORT-ACTING BENZODIAZEPINES | GLAXO GROUP LIMITED (GB) | 2000-11-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148338-A1 | COMPOSITIONS COMPRISING SHORT-ACTING BENZODIAZEPINES | GABRA5, GABRA2, GABRA1 | GABRA1 3/4885GABRA5 1/4885GABRA3 4/4885 |
| US-20230346796-A1 | DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM) | OPRM1, OPRK1, GABRA5 | GABRA1 11/4885GABRA5 3/4885GABRA3 10/4885 |
| US-20210139452-A1 | METHOD FOR PREPARING 3-[(3S)-7-BROMO-2-OXO-5-(PYRIDIN-2-YL)-2,3-DIHYDRO-1H-[1,4]-BENZODIAZEPIN-3-YL] PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN THAT METHOD | GABRA3, GRIK5, GABRA6 | GABRA1 10/4885GABRA5 4/4885GABRA3 1/4885 |
| US-11236064-B2 | Method for preparing 3-[(3S)-7-bromo-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-[1,4]-benzodiazepin-3-yl] propionic acid methyl ester, and compounds useful in that method | GABRA3, GRIK5, GABRA6 | GABRA1 10/4885GABRA5 4/4885GABRA3 1/4885 |
| US-20150224114-A1 | DOSING REGIMEN OF SEDATIVE | GABRA6, GABRA3, GABRA1 | GABRA1 3/4885GABRA5 4/4885GABRA3 2/4885 |
| US-20250360144-A1 | DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM) | OPRM1, OPRK1, GABRA5 | GABRA1 11/4885GABRA5 3/4885GABRA3 10/4885 |
| US-11325911-B2 | Method for preparing 3-[(4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[ 1,2-a][1,4]benzodiazepin-4-yl]-propionic acid methyl ester, and compounds useful in said method | GABRA6, GABRA4, GABRA1 | GABRA1 3/4885GABRA5 6/4885GABRA3 4/4885 |
| US-20120330007-A1 | PROCESS FOR PREPARING 3-[(4S)-8-BROMO-1-METHYL-6-(2-PYRIDINYL)-4H-IMIDAZO[1,2-A][1,4]BENZODIAZEPINE-4-YL]PROPIONIC ACID METHYL ESTER OR THE BENZENE SULFONATE SALT THEREOF, AND COMPOUNDS USEFUL IN THAT PROCESS | GABRA1, GABRA6, GABRA4 | GABRA1 1/4885GABRA5 12/4885GABRA3 7/4885 |
| US-20220152045-A1 | DOSING REGIMEN OF SEDATIVE | GABRA6, GABRA3, GABRA1 | GABRA1 3/4885GABRA5 4/4885GABRA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.